1. Home
  2. AMCX vs SGHT Comparison

AMCX vs SGHT Comparison

Compare AMCX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCX

AMC Networks Inc.

HOLD

Current Price

$9.22

Market Cap

362.6M

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$4.99

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
SGHT
Founded
1980
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.6M
235.0M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
AMCX
SGHT
Price
$9.22
$4.99
Analyst Decision
Sell
Buy
Analyst Count
4
7
Target Price
$7.33
$9.08
AVG Volume (30 Days)
398.6K
314.9K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
132.55
28.16
EPS
N/A
N/A
Revenue
$2,311,801,000.00
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$3.11
52 Week High
$10.28
$9.24

Technical Indicators

Market Signals
Indicator
AMCX
SGHT
Relative Strength Index (RSI) 67.03 57.35
Support Level $6.87 $4.86
Resistance Level $10.09 $5.25
Average True Range (ATR) 0.45 0.40
MACD 0.05 -0.00
Stochastic Oscillator 90.18 57.24

Price Performance

Historical Comparison
AMCX
SGHT

About AMCX AMC Networks Inc.

AMC Networks owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: